Conditions: Herpes Zoster
Keywords: Immunogenicity Safety Herpes zoster Vaccination Haematologic malignancies
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 568
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.

Detailed description:
Amendment to protocol posting:

Increase in sample size, update of country/region-specific information (Sections 5, 6 and 9).

Promotion of secondary to primary objective; related update of primary and secondary outcome measures (Sections 4 and 7).

Arms:
arm 1: Subjects will receive the candidate HZ vaccine (GSK 1437173A). arm 2: Subjects will receive the placebo vaccine.

Interventions: intervention 1: Herpes zoster vaccine (GSK 1437173A) intervention 2: Placebo
Intervention descriptions: intervention 1: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1. intervention 2: 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

Protocol document: